Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Academic Article uri icon

Overview

abstract

  • Gilteritinib induces 2 distinct marrow responses in FLT3-mutated AML: responses with and without differentiation. Ongoing clonal hematopoiesis is ubiquitous during gilteritinib therapy and may promote genetic evolution and drug resistance.

publication date

  • May 28, 2019

Research

keywords

  • Aniline Compounds
  • Leukemia, Myeloid, Acute
  • Pyrazines
  • fms-Like Tyrosine Kinase 3

Identity

PubMed Central ID

  • PMC6538870

Scopus Document Identifier

  • 85067334700

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2018029496

PubMed ID

  • 31122910

Additional Document Info

volume

  • 3

issue

  • 10